Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125098173 | 12509817 | 3 | F | 20160616 | 20160818 | 20160629 | 20160824 | PER | US-SHIRE-US201607867 | SHIRE | 27.30 | YR | F | Y | 62.59000 | KG | 20160824 | PH | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125098173 | 12509817 | 1 | PS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 50 MG, 1X/DAY:QD | 3140497 | 21977 | 50 | MG | CAPSULE | QD | |||||
125098173 | 12509817 | 2 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | Oral | 150 MG, 2X/DAY:BID | 0 | 150 | MG | TABLET | BID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125098173 | 12509817 | 1 | Attention deficit/hyperactivity disorder |
125098173 | 12509817 | 2 | Depression |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125098173 | 12509817 | Drug effect variable | |
125098173 | 12509817 | Mood altered | |
125098173 | 12509817 | Product quality issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125098173 | 12509817 | 1 | 20160616 | 0 | ||
125098173 | 12509817 | 2 | 2012 | 0 |